Fred Grossman
President at COYA THERAPEUTICS, INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dieter Weinand | M | 63 |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 14 years |
| Joseph del Moral | M | 45 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Howard Berman | M | 50 | 4 years | |
| David Snyder | M | 63 | 2 years | |
| Gregory Mayes | M | 55 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 years |
| Ann Lee | M | 62 | 3 years | |
| Dov Goldstein | M | 56 | 3 years | |
| Barry Fishman | M | 67 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 years |
| Ellen Lubman | F | 48 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 years |
| Curtis Weber | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 years |
| Hideki Garren | M | 60 | 3 years | |
| Philip Facchina | M | 62 | 3 years | |
| William Perhacs | M | - | 17 years | |
| Robert Alexander | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 years |
| Arun Swaminathan | M | - | 1 years | |
| Jessica Starman | F | - | - | |
| Jonathan See | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Tim Power | M | - | 18 years | |
| Wilbur Ross | M | 85 | 1 years | |
| Hannan Fleiman | M | 44 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 5 years |
| Anabella Villalobos | M | 65 | 3 years | |
| Dagmar Rosa-Bjorkeson | F | 60 | 4 years | |
| John M. Centanni | M | - | 2 years | |
| Kristen Laguerre | F | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Nathan Bryson | M | 61 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 years |
| Edward Smith | M | 53 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 years |
| Ansbert Gadicke | M | 66 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Michelle Frazier | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nobuhiko Tamura | M | 68 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 5 years |
| James Cornelius | M | 81 | 10 years | |
| Peter R. Dolan | M | 68 | 18 years | |
| Mark Iwicki | M | 57 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 5 years |
| Togo Dennis West | M | 81 | 10 years | |
| Douglas Manion | M | 64 | 11 years | |
| Hiroshi Nomura | M | 66 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 3 years |
| Adrian Hepner | M | 62 | 2 years | |
| Helen Boudreau | F | 58 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 years |
| Carl Decicco | M | 62 | 10 years | |
| David J. Helfgott | M | - | - | |
| Gerald Bruce | M | 68 | 8 years | |
| Louis Gerstner | M | - | - | |
| Alan J. Lacy | M | 70 | 12 years | |
| Michael Grobstein | M | 81 | 13 years | |
| Vicki Sato | M | 75 | 15 years | |
| Robert Williams | M | 75 | 7 years | |
| John Tsai | M | 57 | 11 years | |
| Albert Parker | M | 58 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 1 years |
| Louis J. Freeh | M | 74 | 8 years | |
| James Robinson | M | 88 | 29 years | |
| Yadagiri R Pendri | M | 68 | 7 years | |
| David Wishart | M | - | 10 years | |
| Fu-Min Su | M | - | 6 years | |
| Charles Laranjeira | M | 58 | 2 years | |
| Sheila Gujrathi | M | 53 | 3 years | |
| James Patrick McDermott | M | - | 3 years | |
| John Golubieski | M | 59 | 16 years | |
| Qin Xia | F | 56 | 1 years | |
| James Daniel Guylain Priour | M | 57 | - | |
| John Houston | M | 64 | 6 years | |
| Thomas Gibbs | M | 52 | 5 years | |
| David Cohen | M | - | 8 years | |
| Ramy Ibrahim | M | 49 | 6 years | |
| Randall Owen | M | - | 6 years | |
| Jennifer Herron | F | 54 | 10 years | |
| Ronald Cooper | M | 61 | 7 years | |
| Lena Elisabeth Svanberg | M | 63 | 7 years | |
| Scott Gunther | M | 57 | 4 years | |
| Kevin McManus | M | - | 9 years | |
| David Berman | M | - | 10 years | |
| Cheryl Capps | F | 62 | 13 years | |
| Mark Trudeau | M | 62 | 11 years | |
| Claude Nicaise | M | 71 | 25 years | |
| Andrew Bonfield | M | 61 | 5 years | |
| Wendy Dixon | M | 68 | 8 years | |
| John L. McGoldrick | M | 83 | 10 years | |
| James R. Ellinghausen | M | 65 | 8 years | |
| William Jones | M | 60 | 12 years | |
| Kimberly A. Hendricks | F | 60 | 3 years | |
| Andrew Shenker | M | 69 | 5 years | |
| Freda Lewis-Hall | M | 69 | 5 years | |
| Lynn H. Clark | F | 66 | 8 years | |
| Stuart Tross | M | 57 | 8 years | |
| Ellen Futter | F | 74 | 6 years | |
| Louis Sullivan | M | 90 | - | |
| Tamar Howson | F | 75 | 6 years | |
| Blaine Davis | M | 50 | - | |
| Richard Colonno | M | 74 | 16 years | |
| John P. Amos | M | 57 | 2 years | |
| Walter Kalmans | M | - | 2 years | |
| Lubor Gaal | M | 56 | 9 years | |
| Roger Theodoredis | M | 65 | 3 years | |
| David Ian Johnson | M | 66 | 12 years | |
| Erin E. Lanciani | F | 55 | 5 years | |
| Matthew Ros | M | 57 | 17 years | |
| Angela Ogden | M | - | 1 years | |
| Stephen E. Bear | M | 73 | 7 years | |
| Raymond T. Keane | M | 65 | 20 years | |
| Laurie Alsup | M | 70 | 10 years | |
| Howard Feldman | M | - | - | |
| Quentin Roach | M | 57 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 85 | 85.00% |
| Canada | 14 | 14.00% |
| Australia | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Fred Grossman
- Personal Network